The Antibiotics Business Is Broken—But There's a Fix

The Antibiotics Business Is Broken—But There's a Fix

In one of its final actions, the review suggested that a company bringing a new antibiotic to market could be given a one-time “market entry reward” of $1 billion, enough to repay its R&D cost and reduce pressure to oversell the drug and provoke resistance.